CHA₂DS₂-VASc

Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach.

Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. CHA₂DS₂-VASc reliably identifies patients who are truly low risk.

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation (developed with EACTS) — recommends CHA₂DS₂-VASc for stroke-risk assessment and oral anticoagulation at a score ≥2 in men / ≥3 in women (consider at 1 / 2).